Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenylbutyrate and Valganciclovir in EBV+ Tumors
NCT00387530Phase 2Withdrawn
- Sponsor
- University of California, San Diego
- Start
- May 2006
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sodium phenylbutyrate in gastric cancer (GC), head and neck cancer (HNC), lymphoma and 1 more, sponsored by University of California, San Diego. Primary endpoint: Rate of Epstein-Barr virus (EBV) lytic phase activation by BZLF1 expression at Day 3. Planned start May 2006; status: withdrawn.
02
Drugs
sodium phenylbutyrate
03
Conditions
gastric cancer (GC)head and neck cancer (HNC)lymphomalymphoproliferative disorder (LPD)
Beyond the preview
Go deeper on NCT00387530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387530.